hPD-1/hPD-L1
Nomenclature
C57BL/6JSmo-Pdcd1tm1(hPDCD1)Cd274tm1(hPD-L1)Smoc
Cat. NO.
NM-HU-00100
Strain State
Repository Live
Model Description
Validation Data
Fig1. The expression of human PD-1 and PD-L1 in double humanized PD-1&PD-L1 mice was confirmed by FACS.
Fig 2.Frequency of leukocyte and myeloid subpopulations in the spleen by flow cytometry
Spleen was collected from WT C57BL/6 mice and HO hPD-1/hPD-L1 mice (8-week-old, female, n=3). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the spleen. Bar indicated expressed as mean ± SEM.
Abbr. HO, homozygous; WT, wild type.
Fig 3.Frequency of leukocyte and myeloid subpopulations in the blood by flow cytometry
Blood was collected from WT C57BL/6 mice and HO hPD-1/hPD-L1 mice (8-week-old, female, n=3). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the blood. Bar indicated expressed as mean ± SEM.
Abbr. HO, homozygous; WT, wild type.
Efficacy study
Fig4. In vivo validation of double humanized PD-1&PD-L1 mice. Double humanized mice were inoculated with MC38 cells, and randomly assigned to different groups (n=8) when the tumor grew to a volume of 100 mm3. A combinatorial treatment of anti-PD-L1 and anti-PD-1 demonstrated a noticeable efficacy improvement compared to the same dose of single agent (top) without affecting the animal body weight (Bottom).
You may also like
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreWorkshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
